Our data demonstrate that TNFR1 inhibition through Atrosimab administration efficiently blocked TNFR1-mediated inflammatory responses in a model of acute TNF-mediated inflammation and in experimental arthritis, NASH and EAE. The gene discussed is TNF; the disease is Arthritis.